Portal Innovations

Our Ventures team supports the launch of startups based on University of Michigan technologies and research discoveries. We provide a full suite of resources, services and funding to help you launch sustainable, impactful world changing startups. The Ventures team will engage with you from day one to establish clear and executable commercialization, business formation and funding strategies. As your startup project begins to take form we can provide grant funding and investment capital, as well as business know-how, talent resources and connections to a nationwide network of investors. Whether it is helping you find the perfect team member, investment partner or connecting you with service providers, we have you covered.

Since its genesis at the University of Oxford in 2015, Panacea Innovation has partnered with some of the world’s best sci-entrepreneurs, research bodies, universities and corporates to build more than 280 companies that offer cutting-edge solutions - curating a portfolio of more than GBP£300m in value. Panacea Innovation’s venturing activities are delivered through two complementary arms: Panacea Stars - a technology translation, commercialisation and R&D arm - and Panacea Ventures, the investment management one.

Investing in groundbreaking technologies means actively shaping the future. Passion is what drives us. Look deeper is our approach. About Onsight Ventures Think globally, act locally. We bring together bright minds to create technologies that have a global impact. Based in Innsbruck, Onsight Ventures is setting new momentum for high-tech start-ups in Austria and Europe. Supported by founding partners Hermann Hauser Investment, Round2 Capital, I.E.C.T., and Standortagentur Tirol, Onsight Ventures builds on a Europe-wide network of industry leading start-ups, universities and experts, to work closely with and support outstanding management teams in the implementation of their technology-based business ideas. Our vision – to work with tomorrow's most outstanding entrepreneurs today. Our goal – to support the development of young companies in reaching their goals and thus partake in actively shaping the future. Our core valuesAmbition: BioNTech, a company largely unknown before the COVID crisis, is making history. This has been achieved following the founding of a successful spin-off, led by three physicians - including Tyrolean Christoph Huber, a member of the Onsight advisory board. Excellence: We don't have to look to Silicon Valley or China for inspiration or knowledge; here in Europe we have excellent university and non-institute-based research.There is no lack of innovation. Convinced by their potential, our sweet spot is academic start-ups and university spin-offs. Impact: The 21st century is presenting us and our planet with major challenges. We are convinced that young entrepreneurs can achieve a positive impact with their technologies and business models by pursuing their goals with passion. Our responsibility as an investor is to help sustainable technologies grow both capital and know-how. Integrity: Entrepreneurship is a team sport. The road to building an internationally successful company is a rocky one. That's why trust, honesty and integrity play a crucial role in the long-term cooperation between founder teams and investors.

We are a venture capital firm specialised in seed investment for innovative early stage companies. BGV generally acts as lead investor. Our team is made up of life science experts and business analysts that can guide life science companies’ development throughout the entire research and development process. BioGeneration Ventures leverages its knowledge gained from working with a diverse network. This includes universities, early stage biotech companies and large pharma. We enable a range of sector-relevant expertise to build and accelerate product development and transform entrepreneurs and their companies to become attractive investment opportunities within the life sciences industry. Our Strategy BioGeneration Ventures (BGV) was launched in 2006. We manage over EUR 250 million across four funds. BGV invests in medical and healthcare innovations that have high potential to positively impact patients. BGV works with an ethos founded in sound novel science. We seek those innovations that have a truly differentiated scientific basis, supported by convincing experimental data. These innovations must be compelling and stand out in the global scientific arena. Only innovations that can address a significant unmet medical need are considered for investment. We aspire to invest in solutions that provide substantial healthcare impact. Progressing a project from discovery to clinical proof-of-concept requires a breadth of experience that founding teams usually do not have from the outset. Through our extensive network and experience we help founders build their companies to extend their capabilities. We guide our portfolio companies along their journey from the scientific discovery to a targeted product development track. Together with the founders, we seeks to shape the companies and define the objectives that enable a successful exit. Our partnerships BGV invests in partnerships with other professional investors in life sciences and has built relationships with various academic institutions (such as Leiden University), venture capital investors in the Netherlands, the EU and the US. Forbion: BGV operates a joint venture partnership with Forbion, a leading European life sciences venture capital fund. Mibiton: Mibiton provides loans to enable promising young life sciences companies to purchase equipment. BGV actively supports the investment activities with BGV Managing Partner Edward van Wezel serving as a member of the board. Our Investors: BGV has a broad investor base comprising private equity/wealth managers, pension funds, academic institutions, regional development funds and private investors.

AdBio partners (formerly Advent France Biotechnology) is a venture capital firm investing in early stage life sciences companies in Europe. AdBio partners’ unique strategy combines early-stage investments in promising startups and strong entrepreneurial support to enable and strengthen the company’s growth. As an early-stage investor, we act as a catalyst to create companies based on innovations coming from academic research. We have established relationships with leading research institutions and technology transfer offices in Europe and benefit from the support of strong network of scientific, clinical, industry and financial partners. The operational team is managed by Alain Huriez, MD, Chairman and Managing Partner, and Geoffroy de Ribains, Managing Partner. The team includes seasoned investment professionals with long-standing track records in entrepreneurial ventures, combined with strong scientific, medical and operational expertise.

The EFL program runs from October – May each year. Founders are not required to have a New York University affiliation and do not have to relocate to New York. The program is free for founders – no equity or fees are taken. Other program benefits include: Executive mentorship: Business leaders, serial entrepreneurs, and seasoned executives will help you craft your company’s vision through time-bound, performance-based goals. Access to leading VCs and Investors: Investment mentors will guide you in successfully raising capital, make connections with New York’s investment community, and may even invest in your startup. Guidance from leading scientists: Prominent scientists and researchers across a myriad of verticals will help you mold your technology development strategy. Business development: NYU Stern’s MBA students will support you in a variety of ways based on your specific business needs. EFL team guidance: The EFL’s expert team will keep you on track to accomplishing your goals by optimizing your access to mentors, MBA students, and other resources throughout the program. Corporate services: EFL’s corporate partners donate many hours and hundreds of thousands of dollars worth of in-kind legal, financial, and technological services. Mentorship from business leaders and scientists Endless Frontier Labs’ mentors are business leaders, investors, and scientists drawn from New York’s thriving business and academic institutions and beyond. Our mentors commit substantial time to provide startups with the best advice and connections to maximize their chances of success. Our ValuesFounder Friendly: We are committed to provide programming in the long-term interests of entrepreneurs. We do not take equity or fees from startups. Each core aspect of the program is in the best interests of founders before, during, and after the program. Inclusivity: We are committed to building an inclusive, equitable, and just community now and for our future. We will provide an environment that is free of bias, prejudice, discrimination, and harassment. Performance Orientation: We are committed to (a) selecting founders with extraordinarily bold, new ideas, (b) providing intimate access to outstanding mentors, and (c) eliciting maximum effort from mentors and founders to accelerate the societal impact of breakthrough science.